CAR-T Clinical Fellow – Haematology | University College London Hospitals NHS Foundation Trust

Dyddiad hysbysebu:	16 Chwefror 2026
Cyflog:	Heb ei nodi
Gwybodaeth ychwanegol am y cyflog:	£73,992 per annum + London weighting + out-of-hours
Oriau:	Llawn Amser
Dyddiad cau:	18 Mawrth 2026
Lleoliad:	London, NW1 2BU
Cwmni:	University College London Hospital
Math o swydd:	Cytundeb
Cyfeirnod swydd:	7806431/309-UCLH-7478

Crynodeb

These roles are set within the department of malignant haematology at UCLH with a focus on cellular therapy (including CAR-T) in accordance with JACIE accreditation standards and NHSE guidance. The T-cell Immunotherapy service at UCLH is undergoing significant expansion and the post-holder will be involved in the delivery of (1) licenced/NHSE CAR T-cell products; (2) the academic and commercial CAR T-cell trial portfolio and (3) a portfolio of TCR-transduced T-cell and Tumour Infiltrating Lymphocyte (TIL) therapies for solid tumours which we hope to further cultivate and develop through the appointments.

There will be training in trial design and delivery through involvement in Tumour Management Group meetings for the academic trial portfolio alongside attendance at Site Initiation Visits for new studies. Training regarding the function of apheresis and the stem cell lab will also be provided.

The appointments will be initially for a period of 1 year from August 2026 with the potential for renewal on an annual basis. The roles will provide structured training in cellular therapy and it will be possible for applicants to develop a research project with a view to undertaking an MD/PhD. There will be an honorary contract with the UCL Cancer Institute for the post-holders.

These roles are set within the department of malignant haematology at UCLH with a focus on cellular therapy (including CAR-T) in accordance with JACIE accreditation standards and NHSE guidance. UCLH is an international leader in the delivery of cellular immunotherapies and the post-holder will be involved in the delivery of (1) licenced CAR T-cell products; (2) the academic and commercial CAR T-cell trial portfolio including trials in haematological malignancies and autoimmune diseases and (3) a portfolio of CAR T-cell, TCR-transduced T-cell and Tumour Infiltrating Lymphocyte (TIL) therapies for solid tumours which we hope to further cultivate and develop through the appointments.

UCLH has an extensive cellular therapy clinical trial portfolio and the post holder will receive training and gain comprehensive experience of trial conduct from trial set up through to long term follow-up. Training regarding the function of apheresis and the stem cell lab will also be provided.

University College London Hospitals NHS Foundation Trust (UCLH) is one of the most complex NHS trusts in the UK, serving a large and diverse population. We provide academically led acute and specialist services, to people from the local area, from throughout the United Kingdom and overseas. Our vision is to deliver top-quality patient care, excellent education, and world-class research.


We provide first-class acute and specialist services across eight sites:

• University College Hospital (incorporating the Elizabeth Garrett Anderson Wing)

• National Hospital for Neurology and Neurosurgery

• Royal National ENT and Eastman Dental Hospitals

• University College Hospital Grafton Way Building

• Royal London Hospital for Integrated Medicine

• University College Hospital Macmillan Cancer Centre

• The Hospital for Tropical Diseases

• University College Hospital at Westmoreland Street



We are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women’s health and the treatment of cancer, infection, neurological, gastrointestinal and oral disease. It has world class support services including critical care, imaging, nuclear medicine and pathology.


We are committed to sustainability and have pledged to become a carbon net zero health service, embedding sustainable practice throughout UCLH. We have set an ambitious target of net zero for our direct emissions by 2031 and indirect emissions by 2040.


For the full Person Specification and more information regarding the main responsibilities of this role, please refer to the attached Job Description.


Please note, due to anticipated high volumes of applications, this vacancy may close earlier than the listed closing date. You are advised not to delay submitting your completed application


Come and be a part of the best NHS trust in England to work for, according to our staff*


* UCLH top trust to work at in England - In the most recent NHS staff survey UCLH had the highest percentage of staff who said they would recommend us as a place to work, out of all general acute or acute/community NHS trusts in England – for the third year in a row.


UCLH recognises the benefits of flexible working for staff – To find out more, visit: Flexible working. 


To discover more about what makes UCLH a great place to work, visit: Why Choose UCLH?



This advert closes on Monday 2 Mar 2026

Aelod balch o'r cynllun cyflogwyr Hyderus o ran Anabledd

Gwybodaeth am Hyderus o ran Anabledd

Yn gyffredinol, bydd cyflogwr Hyderus o ran Anabledd yn cynnig cyfweliad i unrhyw ymgeisydd sy'n datgan eu bod yn anabl ac yn bodloni'r meini prawf lleiaf ar gyfer y swydd fel y diffinnir gan y cyflogwr. Mae'n bwysig nodi, mewn rhai sefyllfaoedd recriwtio fel nifer fawr o ymgeiswyr, cyfnod tymhorol ac amseroedd prysur iawn, efallai y bydd y cyflogwr am gyfyngu ar y niferoedd cyffredinol o gyfweliadau a gynigir i bobl anabl a phobl nad ydynt yn anabl. Am fwy o fanylion ewch i Hyderus o ran Anabledd.